Forte Biosciences (NASDAQ:FBRX) Earns “Buy” Rating from Chardan Capital
Forte Biosciences (NASDAQ:FBRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $61.00 price target on the stock. Chardan Capital’s price objective points to a potential upside of 476.02% from the stock’s current price. Separately, Wall […]
Forte Biosciences (NASDAQ:FBRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $61.00 price target on the stock. Chardan Capital’s price objective points to a potential upside of 476.02% from the stock’s current price. Separately, Wall […]
